First Northwest is a bank holding company. Through its subsidiary, First Federal Savings and Loan Association of Port Angeles (First Federal), the company provides products and services focused on the lending and depository needs of the communities it serves. First Federal's lending activities are concentrated in real estate secured loans with first lien one- to four-family mortgage, commercial, and multi-family loans. First Federal also makes construction and land loans, commercial business loans, and consumer loans, consisting mainly of automobile loans and home-equity loans and lines of credit. The company's deposit instruments, including checking accounts, savings accounts and certificates of deposit.

Immunic is a biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. The company is developing three small molecule products: IMU-838 is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme dihydroorotate dehydrogenase; IMU-935 is an inverse agonist of RORgt; and IMU-856 targets the restoration of the intestinal barrier function. The company's main development program, IMU-838, is in Phase 2 clinical development for relapsing-remitting multiple sclerosis and ulcerative colitis, with an additional Phase 2 trial considered in Crohn's disease.

Orthofix International is a medical device company focused on musculoskeletal healing products and services. Co.'s business units are: BioStim, which manufactures, distributes, and provides support services for bone growth stimulation devices; Extremity Fixation, which provides products and solutions that allow physicians to treat a range of orthopedic conditions unrelated to the spine; Spine Fixation, which focuses on the design, development and marketing of a portfolio of implant products used in surgical procedures of the spine; and Biologics, which provides a portfolio of regenerative products and tissue forms that allow physicians to treat a range of spinal and orthopedic conditions.

Y-mAbs Therapeutics is a biopharmaceutical company focused on the development and commercialization of antibody-based therapeutic products for the treatment of cancer. The company has a range of product pipeline, including two pivotal-stage product candidates: naxitamab and omburtamab, which target tumors that express GD2 and B7-H3, respectively. The company is developing naxitamab for the treatment of pediatric patients with relapsed or refractory, high-risk neuroblastoma (NB), and radiolabeled omburtamab for the treatment of pediatric patients with central nervous system, leptomeningeal metastases, from NB.